eFFECTOR Therapeutics Inc

EFTR | $1.92 7.87% 7.29% 150K

(0.0% 1d) (-87.1% 1m) (351.4% 1y) (0.0% 2d) (0.0% 3d) (4.7% 7d) (-10.08% volume)
Earnings Calendar: 2024-03-13
Market Cap: $ 6,566,400
http://effector.com/
Sec Filling | Patents | n/a employees

(US) eFFECTOR is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR’s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes. Each of eFFECTOR’s product candidates is designed to act on a single protein that drives the expression of multiple functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR’s lead product candidate, tomivosertib, is a MNK inhibitor currently being evaluated in KICKSTART, a randomized, double-blind, placebo-controlled Phase 2b trial of tomivosertib in combination with pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC). Zotatifin, eFFECTOR’s inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E. In addition to the company’s oncology focus, zotatifin is being evaluated as a potential host-directed anti-viral therapy in patients with mild to moderate COVID-19 in collaboration with the University of California, San Francisco, under a $5 million grant sponsored by the Defense Advanced Research Projects Agency.

cancer msa defense lung cancer lungs t-cell antiviral covid

add to watch list Paper trade email alert is off

Press-releases

eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
EFTR | $1.92 7.87% 7.29% 150K

| -23.77% | O: -7.07% H: 13.36% C: 6.45%
conference therapeutics

eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
Published: 2024-04-04 (Crawled : 12:30) - globenewswire.com
EFTR | $1.92 7.87% 7.29% 150K

| -88.4% | O: -76.55% H: 13.89% C: -17.78%
lung cancer cell topline trial therapeutics results

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-03-25 (Crawled : 20:00) - globenewswire.com
EFTR | $1.92 7.87% 7.29% 150K

| -87.06% | O: -10.68% H: 9.76% C: 5.04%
year update therapeutics financial results

eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
Published: 2024-02-05 (Crawled : 13:30) - globenewswire.com
EFTR | $1.92 7.87% 7.29% 150K

| -83.14% | O: 0.09% H: 2.37% C: -4.35%
conference life sciences therapeutics

eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Published: 2024-01-29 (Crawled : 21:00) - globenewswire.com
EFTR | $1.92 7.87% 7.29% 150K

| -84.79% | O: -2.22% H: 4.46% C: -1.05%
nasdaq million direct offering therapeutics

eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Published: 2024-01-25 (Crawled : 13:00) - globenewswire.com
EFTR | $1.92 7.87% 7.29% 150K

| -82.11% | O: -10.55% H: 6.52% C: 2.02%
nasdaq million direct offering therapeutics

eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024
Published: 2024-01-09 (Crawled : 13:00) - globenewswire.com
EFTR | $1.92 7.87% 7.29% 150K